methyl 3-aminopyrazine-2-carboxylate : A pyrazine that is substituted by a methoxycarbonyl group at position 2 and an amino group at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 72669 |
| CHEMBL ID | 1866348 |
| CHEBI ID | 145238 |
| SCHEMBL ID | 261104 |
| Synonym |
|---|
| AC-1928 |
| smr001574707 |
| EN300-21697 |
| BB 0253700 |
| nsc-123649 |
| nsc123649 |
| 16298-03-6 |
| mls002707315 , |
| 3-amino-2-pyrazinecarboxylic acid methyl ester |
| AB-323/25048520 |
| methyl 3-aminopyrazine-2-carboxylate |
| OPREA1_525293 |
| inchi=1/c6h7n3o2/c1-11-6(10)4-5(7)9-3-2-8-4/h2-3h,1h3,(h2,7,9 |
| SR-01000639248-1 |
| methyl 3-amino-2-pyrazinecarboxylate, 97% |
| MAYBRIDGE1_007843 |
| methyl 3-aminopyrazinecarboxylate |
| STK503893 |
| A1186 |
| 3-aminopyrazine-2-carboxylic acid methyl ester |
| HMS563M11 |
| methyl 3-amino-2-pyrazinecarboxylate |
| CHEBI:145238 |
| 3-aminopyrazinecarboxylic acid methyl ester |
| methyl 3-amino-2-pyrazine carboxylate |
| AKOS000121301 |
| 2-amino-3-(methoxycarbonyl)pyrazine |
| CCG-49818 |
| einecs 240-387-5 |
| unii-b2b97688nd |
| nsc 123649 |
| b2b97688nd , |
| ec 240-387-5 |
| methyl 2-aminopyrazine-3-carboxylate |
| BP-11960 |
| FT-0601160 |
| AM20070316 |
| S6230 |
| 3-amino-pyrazine-2-carboxylic acid methyl ester |
| SCHEMBL261104 |
| BBL027773 |
| mfcd00010097 |
| SY005164 |
| PS-5260 |
| methyl-3-aminopyrazine-2-carboxylate |
| methyl (2-aminopyrazin-3-yl)formate |
| methyl 2-amino-3-pyrazinylcarboxylate |
| 2-amino-3-carbomethoxypyrazine |
| methyl 3-amino-2-pyrazine-carboxylate |
| methyl 3-amino-pyrazine-2-carboxylate |
| 2-pyrazinecarboxylic acid, 3-amino-, methyl ester |
| pyrazinecarboxylic acid, 3-amino-, methyl ester |
| Q-103337 |
| CHEMBL1866348 |
| DS-0706 |
| DTXSID10167496 |
| F0001-0585 |
| CS-D1517 |
| BCP23206 |
| pyrazinoic acid, 3-amino-, methyl ester |
| methyl2-aminopyrazine-3-carboxylate |
| methyl 3-aminopyrazine-2-carboxylic acid |
| methyl-3-amino-2-pyrazinecarboxylate |
| PB40977 |
| Z104509600 |
| Class | Description |
|---|---|
| pyrazines | |
| methyl ester | Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol. |
| aromatic amine | An amino compound in which the amino group is linked directly to an aromatic system. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| acid sphingomyelinase | Homo sapiens (human) | Potency | 25.1189 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 0.7563 | 0.1000 | 20.8793 | 79.4328 | AID588453; AID588456 |
| ClpP | Bacillus subtilis | Potency | 1.2589 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 7.0795 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.52) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||